Henry Schein (NASDAQ:HSIC) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided EPS guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.99.
Henry Schein (NASDAQ:HSIC) traded up $1.14 during midday trading on Tuesday, reaching $69.52. The company had a trading volume of 2,869,500 shares, compared to its average volume of 2,003,720. The stock has a market cap of $10,911.47, a price-to-earnings ratio of 20.03, a P/E/G ratio of 1.78 and a beta of 1.00. Henry Schein has a twelve month low of $63.01 and a twelve month high of $93.50. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 20th. The company reported $0.97 EPS for the quarter, meeting analysts’ consensus estimates of $0.97. The business had revenue of $3.32 billion during the quarter, compared to analyst estimates of $3.30 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. Henry Schein’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.94 EPS. research analysts anticipate that Henry Schein will post 3.6 EPS for the current fiscal year.
A number of research analysts have issued reports on HSIC shares. Royal Bank of Canada reduced their price objective on Henry Schein from $91.00 to $82.00 and set a sector perform rating for the company in a research note on Tuesday, November 7th. Craig Hallum upgraded Henry Schein from a hold rating to a buy rating in a research note on Tuesday, November 7th. Stifel Nicolaus reduced their price objective on Henry Schein from $89.00 to $77.00 and set a hold rating for the company in a research note on Tuesday, November 7th. Leerink Swann restated a market perform rating and issued a $77.00 price objective (down previously from $87.50) on shares of Henry Schein in a research note on Tuesday, November 7th. Finally, Jefferies Group reduced their price objective on Henry Schein from $89.00 to $74.00 and set a hold rating for the company in a research note on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $83.71.
In other news, Director Barry J. Alperin sold 5,796 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.19% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/20/henry-schein-hsic-issues-fy18-earnings-guidance.html.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.